Steris
STE · What the business does, what can go wrong, and how options sellers approach it
What it does
STERIS makes products and provides services that keep medical and pharmaceutical items clean, sterile and safe to use. Its customers include hospitals, surgery centers, medical device makers and drug manufacturers. The company is incorporated in Ireland with deep roots in the United States.
Its work falls into a few broad areas: infection prevention for hospitals, contract sterilization for device makers, and products and services for biopharma manufacturing.
How it makes money
Revenue mixes equipment sales, recurring consumables and service work. Hospitals buy sterilizers, washers, surgical tables and lights, then keep paying for maintenance, repair and supplies. Device makers pay to have products sterilized at STERIS facilities, using methods such as gamma, electron beam and ethylene oxide. Drug makers buy cleaning and contamination-control products.
The recurring parts tend to be steadier than equipment orders, which depend on customer budgets.
Why investors own it
- Sterilization is a necessity, so demand is tied to procedure volumes and regulation rather than fashion.
- Recurring consumables and services add some predictability.
- Switching suppliers can be costly and slow for customers, because sterilization processes must be validated.
- Growth in medical device and biopharma production supports long-term outsourcing demand.
What can go wrong
- Ethylene oxide faces environmental and health scrutiny, and tighter rules could raise costs or restrict operations.
- Hospital capital budgets can shrink, delaying equipment orders.
- Lower elective procedure volumes can reduce demand for supplies and services.
- Competitors and in-house hospital capabilities can limit pricing.
- Product quality problems or regulatory actions can harm reputation.
What to watch
- Organic revenue growth by segment
- Capital equipment backlog and order trends
- Procedure volumes at hospitals
- Operating margin
- Free cash flow
- Regulatory developments on ethylene oxide
- Debt levels after acquisitions
Options income angle
Options on STE are listed, but activity is lighter than for large, widely held stocks. Bid-ask spreads can be wider, especially for far-from-the-money strikes or longer expirations.
Implied volatility tends to rise ahead of earnings and guidance updates, and regulatory news about sterilization methods can also move it.
One caution for premium sellers: a steady business can still gap sharply on an earnings surprise or regulatory headline, and a short option can then lose far more than the premium collected. Thin liquidity can also make closing a position costlier.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended March 31, 2026, filed May 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
STERIS reported higher revenue and a much larger operating profit for the year ended March 31, 2026, with cash flow and dividends also rising. The risks the filing stresses are specific. They include ethylene oxide (EO) sterilization litigation and regulation, tariffs and the USMCA trade agreement review, tax rules that bite harder because the parent is Irish, and about $1,931.7 million of indebtedness.
How the business did
- Revenues rose 8.7% to $5,935.9 million, from $5,459.5 million. Management credits higher volume, pricing and favorable currency. Service revenues grew 11.1% to $2,875.8 million.
- Income from operations rose 27.1% to $1,101.8 million, from $866.6 million. Pricing, volume, and lower restructuring and litigation costs helped, and the prior year included a $48.2 million Illinois EO settlement expense. Gross profit percentage was 44.2%, against 44.0%. Tariffs took 80 basis points off it and inflation 70 basis points (a basis point is one hundredth of a percentage point).
- Healthcare revenue grew 8.5% to $4,208.6 million, but its operating margin slipped to 24.6% from 25.0% because tariffs and inflation outweighed the gains. AST, the contract sterilization segment, grew 9.6% and its operating margin rose to 46.1% from 44.8%, although its capital equipment sales declined.
- Cash flow from operations was $1,341.4 million and free cash flow (operating cash flow after capital spending) was $982.9 million. The company repurchased $225.0 million of shares and paid cash dividends of $241.8 million, or $2.46 per share.
- The effective tax rate was 25.0%, against 23.2%, on geographic mix and withholding taxes. The company also bought $134.0 million of investments, mostly a noncontrolling stake in a non-U.S. healthcare product manufacturer.
Risks specific to this company
- EO litigation and regulation: The EPA determined EO is carcinogenic, and the company has faced injury lawsuits over emissions. It agreed to pay up to approximately $48.2 million to resolve substantially all pending Cook County, Illinois claims. The claims process is ongoing and needs final court approval.
- EO and device supply: Many medical devices can only be sterilized with EO. If rules curtailed it, the filing warns of device shortages and fewer surgeries, which would hurt the Healthcare business.
- Single-source materials: Cobalt-60 and EO, both needed for AST, have few suppliers and are single-sourced in some regions. Shortages or price increases could hurt operations.
- Tariffs and USMCA: The first joint review of the USMCA is expected to begin July 1, 2026. Changes could affect the company's manufacturing and its suppliers in Canada and Mexico.
- Tax structure: The parent is organized in Ireland, so the company does not expect to benefit from a new U.S.-parent safe harbor under the global minimum tax rules. It could owe extra tax where its rate falls below 15%, and an IRS challenge to its Irish status is a stated risk.
- Debt: About $1,931.7 million of indebtedness is outstanding, including $1,350.0 million of Senior Public Notes. The filing says debt service could limit flexibility for dividends and buybacks. The company was in compliance with its financial covenants.
What management is watching
- Management plans to control costs, grow through internal product and service development, invest in capacity and efficiency, and add acquisitions where they fit.
- Capital spending was $369.0 million. Next year's plans include facility expansions in Healthcare and AST and a multi-year technology upgrade for service and sales workflows.
- On May 5, 2026 the board authorized a new share repurchase program of up to $1,000.0 million.
- Backlog, meaning unfilled capital equipment orders, was $392.1 million in Healthcare and $98.7 million in Life Sciences.
- Management also points investors to free cash flow, constant currency organic growth of 7.3%, and a debt-to-total capital ratio of 21.3%.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
STERIS grew revenues 8.8% to $1,588.6 million for the three months ended September 30, 2026, and income from operations rose to $294.3 million from $265.8 million. The bigger development is the October 11, 2026 agreement to buy Xodus Medical for approximately $2.1 billion in cash at closing, which the company expects to fund mostly with new debt.
How the business did
- Revenue: The quarter's $1,588.6 million compares with $1,460.3 million a year earlier. Six-month revenues increased 8.1% to $3,081.3 million. The company credits higher volume and pricing. Life Sciences revenues rose 17.7% to $170.6 million, with capital equipment up 53.0%. Healthcare rose 8.6% to $1,122.4 million and AST (contract sterilization) rose 5.0% to $295.6 million.
- Profit: Gross profit percentage was 44.7% versus 44.2%. Pricing added 130 basis points (a basis point is one hundredth of a percentage point) and tariff refunds added another 130 basis points, partly offset by material costs (90 basis points) and restructuring costs (50 basis points). Six-month income from operations was $580.1 million versus $511.8 million. Restructuring expenses were $19.1 million versus $2.2 million.
- Margins: Healthcare segment operating margin fell to 24.0% from 25.1%, citing higher inflation, operational investments and lower productivity. Life Sciences rose to 44.4% from 41.3%. The effective tax rate was 25.7% versus 23.9%.
- Cash and capital return: For six months, cash from operations was $656.1 million versus $707.8 million, and free cash flow (operating cash less capital spending) was $492.5 million versus $527.7 million. The company said it used cash to build inventory. It repurchased shares for $200.0 million and paid dividends of $128.4 million, or $1.32 per ordinary share.
What management is watching
- Xodus Medical: The company expects to close by December 31, 2026. Besides the cash price, there is potential earnout consideration of up to $150.0 million. Funding is planned as approximately $2.0 billion of new debt, including approximately $500.0 million under a Delayed Draw Term Loan, plus cash on hand. The company has $1.5 billion of committed bridge financing it expects to replace with permanent financing before closing.
- Restructuring and capital projects: A new North Carolina Center of Excellence for chemistries manufacturing will cost approximately $600 million and lets the company close facilities in St. Louis and Plymouth. Pre-tax charges of approximately $55 million to $70 million are expected through fiscal 2030. A second plan carries charges of approximately $45 million.
- Measures pointed to: Backlog (unfilled capital equipment orders) was $455.5 million in Healthcare versus $427.5 million, and $93.4 million in Life Sciences versus $113.7 million. Management also cites free cash flow and organic growth.
New or changed risks
- Deal may not close: Closing depends on antitrust waiting periods and other conditions. Either side may terminate if the deal is not completed by July 12, 2027 (extended to January 11, 2028 if approvals remain outstanding). A failed deal would leave the company with significant costs and no benefits.
- Disruption while pending: Uncertainty could lead employees to leave and customers or suppliers to delay decisions or change relationships at either company.
- More debt: The company had approximately $1.9 billion of indebtedness at September 30, 2026 and expects approximately $2.0 billion more. Permanent financing terms may be less favorable, and drawing the bridge facility would likely cost more and mature sooner.
Follow STE in Kortex
The Kortex app shows STE's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.